abs46.txt	background		the	majority	of	urothelial	cancers	(uc)	harbor	alterations	inretinoblastoma	(rb)	pathway	genes	that	can	lead	to	loss	rb	tumour	suppressorfunction	palbociclib	is	an	oral	selective	inhibitor	cdk	4/6	restores	rbfunction	and	promotes	cell	cycle	arrest	methods	in	this	phase	ii	trial	patients	with	metastatic	platinum-refractory	ucmolecularly	selected	for	p16	intact	by	immunohistochemistryreceived	125	mg	p	o	daily	21	days	a	28-day	primaryendpoint	was	progression-free	survival	at	4	months	(pfs4)	using	simon'stwo-stage	design	next-generation	sequencing	including	wasconducted	results	twelve	were	enrolled	two	(17%)	achieved	pfs4	withinsufficient	activity	advance	stage	2	no	responses	seen	median	pfswas	1	9	(95%	ci	8-3	7	months)	overall	6	3	months(95%	2-12	fifty-eight	percent	had	grade	â‰¥3hematologic	toxicity	there	cdkn2a	found	correlationof	clinical	outcome	conclusions	did	not	demonstrate	meaningful	selectedpatients	uc	further	development	ofpalbociclib	should	only	be	considered	improved	integral	biomarker	selectionor	rational	combination	other	therapies
